[[:Category:Antiarrhythmics|Antiarrhythmic (Vaughan-Williams class IC)]]
mechanism
String
'"`UNIQ--vote-0000113A-QINU`"' Concomitant β-blocker or CCB is required when used for AF to prevent 1:1 atrial flutter conduction (flecainide can slow atrial rate to a level where AV conduction allows dangerous ventricular rates). CYP2D6 substrate'"`UNIQ--ref-0000113B-QINU`"'.
50 mg PO BID; titrate to 100-200 mg BID; pill-in-pocket 200-300 mg PO single dose for AF conversion
preparations
String
50, 100, 150 mg tablets
fda_max
String
400 mg/d
pill_id
Text
routes
List of String, delimiter: ,
Oral
onset
String
AF conversion within hours of single PO dose
duration
String
12 hours
halflife
String
~14 hours (adults); longer in elderly and renal impairment'"`UNIQ--ref-0000113F-QINU`"'
bioavailability
String
~90% (oral)'"`UNIQ--ref-00001140-QINU`"'
pregnancy
String
Use in fetal SVT (transplacental antiarrhythmic therapy) is established; otherwise weigh against alternatives.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup>
legal
String
[[USLegal:Prescription only|Rx-only]] in US. '''Contraindicated in structural heart disease''' — CAST trial (1989) showed increased mortality from class IC agents in patients with prior MI; modern use is limited to structurally normal hearts'"`UNIQ--ref-00001141-QINU`"'
